Biologics
Jan 22, 2026
Sonomotion Secures FDA Clearance for Break Wave™ Lithotripsy System; Aidoc Earns FDA Clearance for Comprehensive AI Foundation Model in Healthcare; BD and Ypsomed Deepen Partnership to Serve Expanding Biologics Market; Omnia Medical Launches FDA-Approved PsiF DNA™ System to Market; Kardium Publishes PULSAR Pivotal Trial Findings in JACC; NEURO PMR Data Validates Hyperfine’s Diagnostic Precision and Patient-Centered Care
Sonomotion Announced FDA Clearance for its Break Wave™ Lithotripsy Device for Treatment of Kidney Stones On January 21, 2026, SonoMotion, a venture-backed medical device company focused on developing non-invasive solutions for kidney stone treatment, announced that it had received U.S. Food and Drug Admini...
Read More...
Nov 22, 2019
The long journey of Biosimilars: Is it an emerging opportunity?
Biologics are not new drugs, their use as a medicine has been around for over a century. The first use of Biologic drug dates back to the year 1796 when the vaccine to treat smallpox was created.They have been revolutionizing the treatment approaches for the past many years. Hormones, insulin, blood products, cytok...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
